Global Health Data Exchange - Discover the World's Health Data

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Nav

General Info
Geography 
Australia (AUS)
Belgium (BEL)
Bulgaria (BGR)
Croatia (HRV)
Czechoslovakia (Czechia, Slovakia)
Czech Republic
Time period covered 
01/2001 - 12/2008